Purpose: To determine the in vitro effectiveness of Plantago major extract, along with two of its active components, aucubin and baicalein, on the inhibition of Candida albicans growth, biofilm formation, metabolic activity, and cell surface hydrophobicity. Materials and Methods: Twofold dilutions of P. major, aucubin, and baicalein were used to determine the minimum inhibitory concentration (MIC), minimum fungicidal concentration (MFC), and the minimum biofilm inhibitory concentration (MBIC) of each solution. Separately, twofold dilutions of P. major, aucubin, and baicalein were used to determine the metabolic activity of established C. albicans biofilm using a 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-carboxanilide reduction assay. Twofold dilutions of P. major, aucubin, and baicalein were used to determine the cell surface hydrophobicity of treated C. albicans biofilm by a two-phase assay using hexadecane. The hydrophobicity percentage of the cell surface was then calculated. A mixed-model ANOVA test was used for intergroup comparisons. Results: The MICs of P. major extract (diluted 1:2 to 1:8), aucubin (61 to 244 µg/ml), and baicalein (0.0063 to 100 µg/ml) on the total growth of C. albicans were noticeable at their highest concentrations, and the inhibition was dose dependent. The MFC was evaluated after 48 hours of incubation, and aucubin (244 µg/ml) exhibited a strong fungicidal activity at its highest concentration against C. albicans growth. The MBIC indicated no growth or reduced growth of C. albicans biofilm at the highest concentrations of aucubin (61 to 244 µg/ml) and baicalein (25 to 100 µg/ml). Similarly, the effects of these reagents on C. albicans biofilm metabolic activity and hydrophobicity demonstrated high effectiveness at their highest concentrations. Conclusion: P. major extract, aucubin, and baicalein caused a dose-dependent reduction on the total growth, biofilm formation, metabolic activity, and cell surface hydrophobicity of C. albicans. This demonstrates their effectiveness as antifungals and suggests their promising potential use as solutions for C. albicans biofilm-related infections.
some are short-term, such as a course of antibiotic therapy, and some are simply associated with old age. Additionally, recent studies have found that certain types of proteins in saliva may predispose some patients to denture stomatitis, causing disease from a nonfungal relation. 7 Other types of predisposing factors are related to underlying diseases such as immunosuppressive therapy, HIV infection, and diabetes mellitus. 2, 6, 8 The most common clinical manifestation of oral candidiasis is denture stomatitis. 2, 6, 9 It occurs in up to 67% of denture wearers, and its multifactorial etiology makes it difficult to treat. 2, 4, 7 Increased colonization of C. albicans and other types of candida species like C. glabrata seem to be involved in the development of denture stomatitis even when the normal bacterial flora seems not to be greatly altered. 6, 7, 9 This is supported by several studies, which describe the entrapment of yeast cells in irregularities of denture base and denture-relining materials, that could serve as a reservoir of microorganisms. 4, 10, 11 Hence the recurrence of stomatitis is very likely to occur after antifungal therapy is discontinued. Antifungal agents commonly used to treat oral candidiasis patients are of a wide spectrum and if indiscriminately used can cause undesirable side effects and permit the emergence of resistant organisms. This leads to the need to find effective natural solutions capable of inhibiting the growth and biofilm formation of Candida-related fungus not only at tissue level but also in biomaterials like dentures.
The pathogenesis of Candida infections is complex, involving yeast and host factors. The ability of Candida strains to overcome host clearance mechanisms and colonize surfaces depends on the effectiveness of the yeast mechanisms, its capability of adherence, and its growth rate. 11 According to PereiraCenci et al, 4 many studies have demonstrated the adhesion of C. albicans to denture surfaces, and they proposed that the more hydrophobic the surface, the more cell adherence. In other words, the higher the surface free energy, the higher the adhesion of the microorganisms. Furthermore, there seems to be a close relationship between the adherence of C. albicans to plastic surfaces and yeast cell surface hydrophobicity (CSH). This interaction is essential for initial resistance or adherence of yeast to acrylic surfaces, because the more hydrophobic the microorganism, the more adherent the microbes are to surfaces that are likewise hydrophobic. 13, 14 Adhesion often leads to colonization and subsequently induces pathology. 4 Should adherence occur, there is greater opportunity for further Candida binding and in cases of denture stomatitis further formation of "denture plaque."
1 Irreversible adhesion to host tissues and prostheses often leads to biofilm formation. 5 Biofilm is defined as a surface-associated, highly structured community of microorganisms enclosed by self-production of a protective extracellular matrix called extracellular polymeric substance (EPS). 15 These oriented aggregations of microorganisms attach to one another on living or nonliving surfaces, and being embedded within EPS helps maintain biofilm structures. 16 In contrast to planktonic cells, biofilm cells display unique phenotypic traits, the most outstanding of which is their notorious resistance to both antifungal agents and to host immune factors. 8 Biofilm-associated Candida infections are difficult to treat and are a danger to patients. 5 The limitations and restricted target range of current antifungal medications have led to a search for more effective antifungal treatments. 6 To reduce further development of antifungal medication resistance, identifying new methods of preventing and treating candidiasis is necessary. For this reason, new therapeutic strategies using medicinal plants and their components would be of significant importance as alternatives in the prevention and management of C. albicans biofilm formation.
P. major is a perennial herb that belongs to the family of Plantaginaceae. 17 It originated in Europe and Asia. In English it is known as greater Plantain, in French it is known as Plantain, in Portuguese as Tranchagem, and in Spanish as Llantén. 12, 18 It is well known for its wound healing, oral wound healing, analgesic, anti-inflammatory, anti-oxidant, antiviral, and antifungal properties. 12, 19 It contains five classes of eleven biologically active compounds: benzoic compound (vanillic acid), flavonoids (baicalein, baicalin, luteolin), iridoid glycoside (aucubin), phenolic compounds (caffeic acid, chlorogenic acid, ferulic acid, pcoumaric acid), and triterpenes (oleanolic acid, ursolic acid). 20 Many of P. major's medicinal properties may be attributed to two of its biologically active components, aucubin (AU) and baicalein (BE).
AU can be isolated from the leaves of P. major, P. asiatica, and Eucommia ulmoides. [20] [21] [22] It has numerous pharmacological effects such as being antimicrobial, anti-inflammatory, hepatoprotective, choleretic, hemodynamic, antispasmodic, antinociceptive, an inhibitor of RNA and protein biosynthesis in sarcoma 180 cells, and a promoter of dermal wound healing. [21] [22] [23] Additionally, Shim et al 21 concluded that AU is useful for oral wound healing due to its anti-inflammatory effect and that it may be applied as a topical agent to oral wounds. Similarly, Kang et al 23 recommended that AU be further researched and used due to its extensive pharmacological properties.
BE can be isolated from P. major and the traditional Chinese medicinal plant Scutellaria baicalensis Giorgi. 20, 24 Several pharmacological studies of BE have demonstrated its anti-oxidative, antimicrobial, and neuro-protective effects. 8 Other studies have demonstrated BE has anti-inflammatory and anticancer effects. 20, 25 With respect to its antifungal aspect, BE has been found to inhibit C. albicans growth and its biofilm formation. 8, 26 Additional studies have found that BE also exhibits an in vitro synergism with fluconazole on C. albicans. 27, 28 Kang et al 29 found that BE could not induce apoptosis in C. albicans and suggested that BE affected fungal growth via different pathways.
To date, only a few studies have investigated the role of P. major extract, AU, and BE as antifungal agents against C. albicans growth, biofilm formation, metabolic activity, and hydrophobicity. Therefore, it would be of significant advantage to find new prospective natural resources to eradicate C. albicans biofilm-related infections. The aim of this study was to assess the in vitro effects of P. major extract, along with two of its active components (AU and BE) on the inhibition of C. albicans growth, biofilm formation, metabolic activity, and cell surface hydrophobicity. The hypothesis was that P. major extract, AU, and BE will cause dose-dependent reductions on C. albicans growth, biofilm formation, metabolic activity, and cell surface hydrophobicity, when compared to the negative control group.
Materials and methods
Fungal strain, growth medium, and antifungal agents C. albicans was obtained from the American Type Culture Collection (ATCC). C. albicans ATCC 10231 was chosen because is a widely used clinical isolate in many C. albicans studies. The strain was originally isolated from a patient with bronchomycosis. 30 Stock cultures were stored at -80°C, passaged onto a blood agar plate and incubated in 95% O 2 /5% CO 2 at 37°C prior to use. C. albicans cells were inoculated into 5 ml of yeast-peptone-dextrose (YPD) broth medium (1% w/v yeast extract, 2% w/v peptone, 2% w/v dextrose; Fisher Scientific, Newark, DE). Thereafter, batches of inocula were incubated overnight in an orbital shaker (120 to 150 rpm) at 30°C. 1, 5, 8, 12, 15, 22 C. albicans grew in the budding-yeast phase under these conditions.
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P. major extract was purchased in 30× potency containing 20% alcohol (Washington Homeopathic Products, Berkeley Spring, WV).
31 P. major extract was diluted with YPD media by twofold dilutions up to 1:512. This potency of P. major extract contains 0.5 µg/ml of AU and 0.425 µg/ml of BE 20 (Table 1) .
AU and BE were obtained from Sigma-Aldrich (St Louis, MO). Both components were dissolved in concentrations ranging from 0 to 244 µg/ml −1 in dimethyl sulfoxide (DMSO) and stored at -20°C. 8, 20 The final concentration of DMSO used alone in all assays was not inhibitory towards C. albicans in agar diffusion assays (data not shown).
Minimum inhibitory concentration and minimum fungicidal concentration
The minimum inhibitory concentration (MIC) is the lowest concentration of an agent that inhibits the visible growth of a microorganism, and the minimum fungicidal concentration (MFC) is the lowest concentration of the agent that kills the fungus. 32 The MICs of P. major extract, AU, and BE against C. albicans were determined by twofold dilutions with YPD media in sterile 96-well flat-bottom microtiter plates (MTP) (Fisher Scientific). P. major extract 30× in 1:2 n nine dilutions, AU concentrations ranging from 0.96 to 244 µg/ml, and BE from 0.006 to 100 µg/ml in YPD (190 µl) were added to 96-well MTP with 10 µl of an overnight culture of C. albicans and incubated for 24 or 48 hours at 37°C. The total yeast growth in the presence of the agents was estimated using a microtiter plate reader (Spectra Max 190; Molecular Devices, Sunnyvale, CA) at a 595 nm wavelength after incubation. The MIC was determined as the lowest concentration of the reagents that yielded a change in OD from the control of ࣙ0.050. The negative control group was YPD inoculated with C. albicans.
To determine the MFC, 10 µl from the 96-well MTP with reagent concentrations ࣙ the MIC were transferred onto blood agar plates (Fisher Scientific) and incubated in 95% O 2 /5% CO 2 at 37°C . The MFC was defined as the lowest concentration of the reagents that had no visible yeast colonies on the agar plates after 48 hours of incubation.
Minimum biofilm inhibitory concentration
The minimum biofilm inhibitory concentration (MBIC) is the lowest concentration of an agent that inhibits the visible biofilm formation of a microorganism. 32 The MBIC was determined by the same twofold dilution of P. major extract, AU, and BE. The same 96-well MTP was used after the MIC was determined. The planktonic culture fluid was gently shaken out, fixed with 200 µl of 10% formaldehyde for 30 minutes, and stained with 200 µl of 0.3% crystal violet for 30 minutes. After washing the biofilm twice with sterile water, crystal violet was extracted from the biofilm cells by incubation of 200 µl of 2-propanol for 1 hour. The absorbance was read at 490 nm. The control group was YPD inoculated with C. albicans.
Biofilm metabolic activity
The metabolic activity of C. albicans was measured using a method described by Pierce et al. 15 This technique requires 24 hours established C. albicans biofilms on the bottom of the 96-well MTP, coupled with a colorimetric method that measures the metabolic activities of biofilm cells based on the reduction of 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-carboxanilide (XTT; Sigma). Upon processing by metabolically active cells, XTT yields a water-soluble formazan-colored product that is measured in a spectrophotometer. The XTT-reduction assay indicates an excellent correlation between cellular density and metabolic activity, thus providing a semi-quantitative measurement of biofilm formation. This colorimetric assay is noninvasive and nondestructive, requiring minimal post-processing samples. Furthermore, this correlates with cell viability, which is particularly useful for measuring the effects of antifungal agents on biofilm cells. 2, 15, 33 The 96-well MTP were seeded for 24 hours with 10 µl of a C. albicans overnight culture in 190 µl of YPD without the reagents to allow biofilm to grow, followed by another 24 hours of growth in YPD supplemented with twofold dilutions of P. major extract, AU, and BE. C. albicans planktonic cells in the 96-well MTP were gently shaken out and 200 µl of XTT/menadione reagent added. 2, 17 The plates were kept in the dark for 2 hours at 37°C in an atmosphere of 95% O 2 /5% CO 2 . After incubation, 120 µl of the solution was transferred to a blank MTP, and any color change was detected by measuring the absorbance at 490 nm in a spectrophotometer. The negative control group was YPD inoculated with C. albicans.
Cell surface hydrophobicity assay
The cell surface hydrophobicity (CSH) of C. albicans was determined by measuring the yeast adherence to a waterhydrocarbon two-phase assay using hexadecane.
14 Twofold dilutions of P. major extract, AU, and BE in YPD (3 ml) were added to six-well tissue culture plates with 150 µl of an overnight inoculum of C. albicans and incubated for 24 hours at 37°C. Briefly, biofilm cells were scraped off the bottom of the culture plates and suspended in 1.5 ml of YPD to yield an optical density of approximately 1.0 at 620 nm. From this cell suspension, 1.3 ml was pipetted into borosilicate glass tubes (18 mm × 75 mm). From each tube, 100 µl of the cell suspensions were pipetted into wells of a 96-well MTP. The plate was read at 620 nm and designated as the initial OD of the cell suspension. The 1.2 ml of cell suspension remaining in the glass tubes was overlaid with 0.3 ml of hexadecane. The phases were vigorously mixed and vortexed for 3 minutes and allowed to separate for 15 minutes. The lower aqueous phase was carefully withdrawn with a pipette, and 100 µl was added to each microtiter well. The absorbance was read and noted as the final OD of the aqueous phase. Tubes without the reagents served as the control group. The percentage hydrophobicity of the yeast cell surface was calculated by the following formula: %CSH = (1-final OD of aqueous phase/initial OD of cell suspension) × 100.
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Statistical analysis
The different experiments were compared for differences in total growth, biofilm formation, biofilm metabolic activity, and cell surface hydrophobicity using a mixed ANOVA. The ANOVA included a fixed effect for the 1:2 n nine dilutions of the P. major extract, AU, and BE, and a random effect for the experiment. Fisher's protected least significant differences was used to control the overall significance level at 5%. Distribution of the data was examined, and a transformation of the data was used.
With a sample size of 144 twofold dilutions for each reagent for each of four experiments, the study had 80% power to detect differences between groups of 0.05 for total growth, biofilm formation, and cell surface hydrophobicity and differences between groups of 0.025 for biofilm metabolic activity. The calculations assumed two-sided tests each conducted at a 5% significance level and within-group standard deviations of 0.05 for biofilm formation, 32 biofilm metabolic activity, 10 and cell surface hydrophobicity. 8 All data were expressed as mean values with the corresponding standard deviations.
Results
P. major extract (diluted 1:2 to 1:8), AU (61 to 244 µg/ml) and BE (0.0063 to 100 µg/ml) demonstrated clear inhibition against C. albicans growth (Fig 1) . These differences were statistically significant (p < 0.0001). The data also indicated that BE was more effective at lower concentrations (ࣙ 0.0063 µg/ml) than P. major and AU.
The MFC, after 48 hours of incubation, indicated that AU had a noticeable fungicidal activity against C. albicans growth at its highest concentration of 244 µg/ml (Table 2 ). In contrast, P. major extract and BE demonstrated some fungicidal activity against C. albicans but this was not significant. AU (61 to 244 µg/ml) and BE (25 to 100 µg/ml) revealed a significant dose-dependent reduction against C. albicans biofilm formation when compared to the negative control group (p < 0.0001; Fig 2) . Lower concentrations of aucubin (1 to 31 µg/ml) and baicalein (0.4 to 12.5 µg/ml) also produced some effect on C. albicans biofilm formation, but this was not statistically significant as well as for all the concentrations of P. major extract.
To provide a more quantitative assessment of cellular activity of established C. albicans biofilm in the presence or absence of the reagents, the ability of the yeast to reduce XTT was measured (Fig 3) . The inhibitory effects of C. albicans metabolic activity were limited to P. major extract (diluted 1:2; p < 0.0159) and AU (244 µg/ml; p < 0.0001). Clearly the inhibition was dose dependent only at the highest concentrations of these two reagents and was statistically significant. The results also demonstrated that the inhibitory effects were active on C. albicans that had already grown in an established biofilm, which usually are the most problematic to treat. On the other hand, BE demonstrated no inhibition on the metabolic activity of C. albicans.
To examine the effect of P. major, AU, and BE on the yeast adherence mechanism, the cell surface hydrophobicity of treated C. albicans biofilm was measured by a two-phase separation method using hexadecane (Fig 4) . The water-hydrocarbon two-phase assay demonstrated a decrease in hydrophobicity of C. albicans biofilm at only the highest concentrations of AU (244 µg/ml; p < 0.0048) and BE (100 µg/ml; p < 0.0375) when compared to their control group; however, P. major extract had little effect on the CSH of the yeast.
Discussion
Biofilm-associated Candida infections are a danger to patients and are challenging to treat because of the complex pathogenesis that involves not only the yeast but host factors as well. 1, 17 The present study demonstrated that the P. major extract, aucubin, and baicalein effectively inhibited C. albicans growth, while the active components of the plant (AU and BE) at higher concentrations exerted strong inhibitory effects against C. albicans biofilm formation and additionally displayed strong fungicidal activity against the yeast. These results are in agreement with earlier data that depicted the usefulness of the reagents in having antimicrobial activities. 8, 12, 17, 19, [21] [22] [23] [27] [28] [29] 34 Ever since ancient times, people have looked to nature for cures. Plants have been used because of their effectiveness, low cost, and accessibility. Medicinal plants are a valuable natural resource due to their antimicrobial activities. Their side effects are often less severe than synthetic medications. 12, 34 They play a principal role in the health care systems of rural and remote communities where the population depends on folklore and herbal medicines. MICs of (A) Plantago major extract, (B) aucubin, and (C) baicalein on the total growth of C. albicans after 24 to 48 hours at 37°C. The data are expressed as mean absorbance (595 nm) ± S.E.M. *P < 0.05, **P < 0.01 when compared with the respective control groups.
P. major is an herb that has been used worldwide for hundreds of years for its medicinal properties. This natural resource would potentially benefit the oral health of at-risk populations, such as denture wearers, debilitated elderly, immunocompromised individuals like neonates, and other populations with fungal infections caused by C. albicans. Appropriate further studies will be necessary to investigate alternative medical uses of the plant extract and components for their routes of administration such as, but not limited to, mouth rinses, troches, creams, ointments, and/or in combination with existing antifungal agents. Topical application of the reagents would be rather safe, and their cytotoxicity should not be a deterrent as this is supported by Reina et al's study 20 that concluded that P. major and BE were not cytotoxic at any of the concentrations examined, and AU was cytotoxic only at the concentration of 100 µg/ml, when studied on human neutrophils. Even though in the present study AU (244 µg/ml) at a higher concentration had an effect on C. albicans viability, a medication such as a mouthwash containing this solution would not have much potential of toxicity in the oral cavity tissues and other tissues not in direct exposure to neutrophils.
Furthermore, in accordance with Shim et al 21 AU was suggested as a potentially safe drug to use in the oral cavity. Most importantly, consider that the reduction in C. albicans viability and biofilm formation obtained from treatment with P. major, AU, and BE at lower concentrations may be sufficient for a patient's immune system to completely eradicate C. albicans related infections.
The ability of these three agents to inhibit C. albicans biofilm formation was dose dependent on their concentrations. Other studies 8, [27] [28] [29] have also supported this dose-dependent relation on the inhibition of C. albicans biofilm formation. Additionally, this study found that AU was the most effective in the decrease of C. albicans biofilm formation and the only agent to maintain the inhibition of viability of the yeast for more than 48 hours.
The metabolic activity of C. albicans biofilm formation was assessed using XTT reduction of tetrezolium to a tetrazolium formazan product by mitochondrial-active C. albicans in the presence of menadione. 29 The correlation between cellular density and metabolic activity provides an excellent semi-quantitative measurement of biofilm formation. 15 The colorimetric assay is noninvasive and nondestructive, requiring minimal post-processing sampling. This also correlated with cell viability, which is particularly useful for measuring the effects of antifungal agents on biofilm cells. 2, 15 Among the three reagents, AU (244 µg/ml) and P. major extract (diluted 1:2) exerted an effect towards C. albicans established biofilm metabolic activity; however, BE did not exhibit inhibition of the metabolic activity of C. albicans biofilm at any of its concentrations. This correlates with the data from Kang et al 29 who demonstrated that BE could not induce apoptosis in C. albicans yet affected fungal growth via a different pathway. The results in this study indicated that BE affected C. albicans biofilm formation via cell surface hydrophobicity, correlating with the findings of Cao et al. 8 BE affects the growth surface of C. albicans composition from true hyphae to yeast cell and pseudo-hyphae after treatment. P. major extract and AU behaved similarly to BE at their highest concentrations, and based on the growth inhibitory effects they contributed to poor biofilm formation. This therefore suggests their effectiveness Figure 3 The biofilm metabolic activity of (A) Plantago major extract, (B) aucubin, and (C) baicalein on established C. albicans biofilm formation after 48 hours at 37°C. The data are expressed as mean absorbance (490 nm) ± S.E.M. *P < 0.05, **P < 0.01 when compared with the respective control groups.
in preventing C. albicans colonization and more importantly in preventing biofilm from becoming resistant.
The resistance of biofilm is likely multifactorial and among many mechanisms it may be due to the yeast cell surface hydrophobicity (CSH). CSH is important for the regulation of the pathogenicity of C. albicans biofilm, since elevated CSH Figure 4 The cell surface hydrophobicity of (A) Plantago major extract, (B) aucubin, and (C) baicalein on C. albicans biofilm after 48 hours at 37°C. The relative hydrophobicity of the control group was set at 1.0. The data are expressed as mean relative hydrophobicity ± S.E.M. *P < 0.05, **P < 0.01 when compared with the respective control groups.
causes increased adhesion of the organism to tissue surfaces and biomaterial surfaces. Many studies have demonstrated that the more hydrophobic the microorganism, the more adherent the cells are to biomaterial surfaces. Furthermore, other studies have shown that C. albicans are less hydrophobic when compared to C. tropicalis and relatively hydrophilic when compared to C. glabrata. 4, 11 Raut et al 5 stated that C. albicans is known to regulate cell surface hydrophobicity status according to growth phase, environment, and nutritional conditions, making this mechanism difficult to study. In the present study, decreased CSH was observed at the highest concentrations of AU (244 µg/ml) and BE (100 µg/ml), where the increased effects of biofilm inhibition were noted. Cao et al 8 also described this negative correlation.
Further investigations to examine the role of P. major extract, AU, and BE in acrylic and nylon denture base materials and their role in the inhibition of C. albicans biofilm formation are needed. Also, further studies may test the agents' solution in human-affected tissues and their effectiveness against the growth of other non-albicans Candida species. Kang et al 23 suggested that AU be further researched and used as a feasible antifungal medication, and in accordance with this study, AU has the potential to be used as an antifungal rinse against the growth of C. albicans due to its outstanding fungicidal properties revealed. Several other biologically active components of P. major extract should also be considered because this study showed that AU and BE at concentrations within the plant had little or no inhibitory effect against C. albicans biofilm formation when tested individually; however, those same concentrations, within the plant extract, displayed inhibition against C. albicans growth and metabolic activity. Therefore, our findings show that P. major benefits from its antifungal properties from a combination of the plant's eleven biologically active components working together, giving the plant its medicinal properties.
